The US FDA has approved Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify (aripiprazole) for the treatment of irritability in patients aged six to 17 years with autism.
The US FDA has approved Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify (aripiprazole) for the treatment of irritability in patients aged six to 17 years with autism.
The 5-HT2A and dopamine D2 antagonist is already approved in the US for treatment of schizophrenia, bipolar disorder and major...
Create an account to read this article
Already a subscriber?
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
